In vitro idiotypic suppression of chronic lymphocytic leukemia lymphocytes secreting monoclonal immunoglobulin M anti-sheep erythrocyte antibody.

Abstract

A B S T R A C T

Cellular localization of rheumatoid factor idiotypes.

“…This is clearly the consequence of an interaction of the antibodies with the membrane idiotypes of the precursor lymphocytes; it is similar to the suppression of other idiotypes in culture, by consequence of the addition of the corresponding antibodies, as reported by Mudawwar and by Bona and Fauci (25,26).…”

Suppression of in vitro monoclonal human rheumatoid factor synthesis by antiidiotypic antibody. Target cells and molecular requirements.

“…In agreement with animal studies (5)(6)(7)(8), the capacity of antiidiotypic antibody to suppress human idiotype expression has been demonstrated both in vitro (32)(33)(34) and in vivo (35) (Fig. 3), the IgG fraction was approximately five times more effective than the F(ab')2 preparation in suppressing in vitro IgM RF release by the patient's blood MNL.…”

Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: A guide for immunotherapy

“…Using the animal model, the L2C leukaemia of strain 2 guinea pigs, which has many features in common with human B cell neoplasms (Stevenson et al, 1977) (Milburn & Lynch, 1982). However, in a study of human chronic lymphocytic leukaemia with cells secreting an IgM paraprotein, sheep anti-idiotypic antibody did inhibit secretion (Bona & Fauci, 1980). The guinea pig leukaemia is convenient to study since the monoclonal anti-idiotype does not affect the subsequent assay of IgM, and using this system no inhibition of secretion was detected over the time period studied.…”

“…Other factors to be considered include the amount of anti-idiotypic antibody bound by the target cells, and the metabolic consequenceg of binding. There have been reports that anti-idiotypic antibodies can switch off secretion of Ig by neoplastic B lymphocytes (Bona & Fauci, 1980) although this seems not to be true for plasma cells (Milburn & Lynch, 1982): this could be important in planning immunotherapeutic schedules. Consumption of antibody would also occur due to the processes of modulation and endocytosis (Gordon & Stevenson, 1981) after which there may be a slow re-expression of antigen (Glennie et al, 1979).…”